证券之星消息，9月9日生物制品板块较上一交易日下跌1.42%，百普赛斯领跌。当日上证指数报收于 3807.29，下跌0.51%。深证成指报收于12510.6，下跌1.23%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688331 | 荣昌生物 | 104.09 | 11.92% | 20.79万 | 21.93亿 | | 300357 | 我武生物 | 33.06 | 1.88% | 17.98万 | 5.9067 | | 688180 | 君实生物 | 48.26 | 1.54% | 26.84万 | 13.23 乙 | | 002581 | ST未名 | 7.71 | 1.18% | 7.66万 | 5908.98万 | | 836547 | 元锡晶海 | 30.34 | 0.40% | 2.62万 | 7882.88万 | | 600211 | 西藏药业 | 55.62 | 0.16% | 21.25万 | 11.86亿 | | 000403 | 派林生 ...

9月9日，百普赛斯跌5.05%，截至发稿，报57.40元/股，成交1.38亿元，换手率1.86%，总市值96.34亿 元。 资料显示，北京百普赛斯生物科技股份有限公司位于北京市大兴区北京经济技术开发区宏达北路8号4幢 4层,5幢4层，成立日期2010年7月22日，上市日期2021年10月18日，公司主营业务涉及提供重组蛋白等 关键生物试剂产品及技术服务。主营业务收入构成为：重组蛋白82.27%，抗体及其他试剂12.88%，技 术服务3.04%，其他(补充)1.80%。 从基金十大重仓股角度 数据显示，天弘基金旗下1只基金重仓百普赛斯。天弘医疗健康A（001558）二季度持有股数41.42万 股，占基金净值比例为5.9%，位居第七大重仓股。根据测算，今日浮亏损失约126.35万元。 天弘医疗健康A（001558）成立日期2015年6月30日，最新规模2.51亿。今年以来收益48.85%，同类排 名621/8179；近一年收益59.58%，同类排名1865/7984；成立以来收益87.36%。 天弘医疗健康A（001558）基金经理为吕俏。 截至发稿，吕俏累计任职时间251天，现任基金资产总规模5.02亿元，任职 ...

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 68.12 RMB based on a 2025 PE of 60X, which is slightly discounted compared to peers due to stable operations [5][9]. Core Insights - The company's revenue continues to grow rapidly, with domestic demand gradually recovering. The introduction of new products in the R&D pipeline is expected to open up additional demand opportunities [2][5]. - In the first half of 2025, the company achieved a revenue of 387 million RMB, representing a year-on-year increase of 29.38%. The net profit attributable to shareholders was 83.80 million RMB, up 47.81% [5][9]. - The domestic revenue reached 123 million RMB, reflecting a growth of 36.65%, while overseas revenue was 258 million RMB, increasing by 22.94% [5][9]. - The company has effectively controlled its expense ratios, leading to improved profitability. The gross profit margin for the first half of 2025 was 90.14%, and the net profit margin was 21.53%, an increase of 3.59 percentage points year-on-year [5][9]. Financial Summary - The financial summary indicates a strong growth trajectory, with total revenue projected to reach 840 million RMB in 2025, up 30.2% from the previous year. Net profit attributable to shareholders is expected to be 191 million RMB, a 53.9% increase [4][6]. - The company has increased its R&D investment, expanding its team to 279 personnel and diversifying its product offerings, with over 5000 products sold [5][9]. - The report highlights the successful development of nearly 50 GMP-grade products in the CGT field and a range of high-quality products in the ADC field [5][9].

Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].

Summary of Key Points Core Viewpoint - The latest financing balance of the ChiNext market is 469.46 billion yuan, showing a decrease of 3.18 billion yuan compared to the previous period, with 17 stocks experiencing a financing balance growth of over 10% and 23 stocks seeing a decline of over 10% [1]. Financing Balance Overview - As of September 4, the ChiNext index fell by 4.25%, with a total margin balance of 470.97 billion yuan, a decrease of 3.25 billion yuan from the previous trading day. The financing balance is 469.46 billion yuan, down by 3.18 billion yuan, while the securities lending balance is 1.51 billion yuan, down by 64.33 million yuan [1]. - Among the 445 stocks with increased financing balances, 17 stocks saw an increase of over 10%. The largest increase was for Shangneng Electric, with a financing balance of 738.61 million yuan, up by 60.76% [1][3]. Stocks with Increased Financing Balances - The stocks with the highest financing balance increases include: - Shangneng Electric: 738.61 million yuan, +60.76%, closing price 34.12 yuan, +13.32% [3]. - Baipusais: 94.00 million yuan, +18.99%, closing price 60.40 yuan, -7.79% [3]. - Kailong Gaoke: 46.23 million yuan, +16.27%, closing price 15.29 yuan, +0.92% [3]. - The average increase for stocks with over 10% growth was 1.22%, with notable performers including Shangneng Electric, Pinwo Food, and Penghui Energy [1]. Stocks with Decreased Financing Balances - A total of 498 stocks saw a decrease in financing balances, with 23 stocks experiencing a decline of over 10%. The largest decrease was for Boyuan Shares, with a financing balance of 11.83 million yuan, down by 37.80% [4]. - Other significant declines include: - Songsheng Shares: 7.55 million yuan, -32.62% [4]. - Youyou Green Energy: 11.74 million yuan, -30.99% [4]. Capital Flow Analysis - On September 4, among the stocks with increased financing balances, 11 stocks saw net inflows of main funds, with Penghui Energy and Shangneng Electric leading with net inflows of 139 million yuan and 133 million yuan, respectively [2]. - Conversely, six stocks experienced net outflows, with Xian Dao Intelligent and Baipusais seeing the largest outflows of 192 million yuan and 22.51 million yuan, respectively [2].

从资金流向上来看，当日生物制品板块主力资金净流出11.3亿元，游资资金净流入2.76亿元，散户资金 净流入8.54亿元。生物制品板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，9月4日生物制品板块较上一交易日下跌2.63%，百普赛斯领跌。当日上证指数报收于 3765.88，下跌1.25%。深证成指报收于12118.7，下跌2.83%。生物制品板块个股涨跌见下表： ...

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is experiencing a decline in stock price and trading volume, while also benefiting from its innovative biotechnological developments and international revenue growth due to currency depreciation [1][4]. Group 1: Company Performance - On September 4, the company's stock dropped by 7.79%, with a trading volume of 350 million yuan and a market capitalization of 10.138 billion yuan [1]. - For the first half of 2025, the company achieved a revenue of 387 million yuan, representing a year-on-year growth of 29.38%, and a net profit of 83.804 million yuan, up 47.81% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan in the last three years [10]. Group 2: Product Development and Innovations - The company has developed a range of high-quality recombinant proteins targeting various diseases, which supports the research and production of biopharmaceuticals [2]. - It has launched a specific antibody targeting the CD19 antigen for CAR-T cell therapy, enhancing detection methods and expanding its product offerings in cell and gene therapy [2]. - The company is actively developing products related to monkeypox virus prevention and treatment, having already launched several recombinant proteins, antibodies, and test kits [2]. Group 3: Market Position and Recognition - The company has been recognized as a "specialized and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [3]. - As of the 2024 annual report, overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the yuan [4]. - The company operates in the pharmaceutical and biotechnology sector, focusing on recombinant proteins, antibodies, and technical services, with a revenue composition of 82.27% from recombinant proteins [8].

Key Points - The core viewpoint of the articles highlights significant corporate announcements, including project investments, contract awards, share buybacks, and operational data, indicating various companies' strategic movements and financial performance [1][2]. Company Announcements - Zhaoxiang Technology's sulfide solid electrolyte project is currently in the pilot test stage and has not yet generated sales revenue [1] - Gansu Energy plans to invest approximately 4.089 billion yuan in the construction of a 1 million kilowatt wind-solar integrated project in Minqin [1] - Donghong Co., Ltd. signed a contract worth 109 million yuan for the procurement of pressure steel pipes and accessories [1] - Zhangjiang Hi-Tech's subsidiary intends to transfer 100% equity and related debts of Shanghai Jixin Rui Architectural Technology [1] - Baipusais completed a share buyback, spending a total of 29.8504 million yuan to repurchase 612,700 shares [2] Operational Data - Changyuan Power reported a total power generation of 3.771 billion kilowatt-hours in August, a year-on-year decrease of 6.03% [2] - Jindi Group achieved a cumulative contract amount of 21.95 billion yuan from January to August, reflecting a year-on-year decline of 53.91% [2] Shareholding Changes - Shareholder Zhong Yinghao of Yongfenghua plans to reduce his holdings by no more than 2% [2] - Yidongxing and Zhao Yanxing of Baolande intend to collectively reduce their holdings by no more than 3% [2] - Guokai Manufacturing Fund and Guokai Science and Technology plan to reduce their holdings in Xinke Mobile by no more than 1% [2] Other Developments - Changqing Technology plans to issue convertible bonds to raise no more than 800 million yuan [2] - Tieliu Co., Ltd. signed a framework agreement with the Yangtze River Delta Hart Robot Industry Technology Research Institute [2]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

（编辑 李家琪） 证券日报网讯 9月3日晚间，百普赛斯发布公告称，公司于2024年10月9日至2025年8月28日期间，通过 股份回购专用证券账户以集中竞价交易方式累计回购股份数量为612，700股，占公司总股本的 0.3650%，最高成交价为54.83元/股，最低成交价为41.82元/股，成交总金额为29，850，432.20元（不含 交易费用）。本次回购金额已达到回购方案中回购资金总额下限人民币2，000万元，且未超过回购资金 总额上限人民币4，000万元（均含本数），本次回购方案实施完毕。 ...